See our latest analysis for 10x Genomics.
Despite 10x Genomics’ innovations keeping it in the spotlight, the share price has pulled back in recent months, leading to a one-year total shareholder return of -36%. This reflects cooler sentiment compared to earlier optimism. The broader picture shows momentum has faded recently, as investors digest the company’s long-term prospects and valuation shifts.
If this makes you curious about what else might be gathering momentum, you can broaden your search and discover fast growing stocks with high insider ownership
With the stock trading below analyst targets despite weak returns, investors may wonder if 10x Genomics is undervalued or if recent results mean the market has already accounted for its future growth. Could this be a buying opportunity?
Most Popular Narrative: 16% Undervalued
The latest narrative from market analysts places 10x Genomics’ fair value above its last closing price of $12.64, suggesting that recent market pullbacks may not have fully reflected the company’s future prospects. This valuation points to an opportunity if key catalysts play out as expected in the coming years.
Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale. This positions 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, which may support long-term revenue and recurring, high-margin consumables sales.
Want to see what’s fueling this bullish projection? The secret lies in ambitious revenue and margin assumptions baked into analyst forecasts. Uncover which big trends and numbers set the target price above the latest market level to see what most investors are missing.
Result: Fair Value of $15.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ongoing macroeconomic and funding uncertainty, combined with shrinking pricing power on core products, could easily disrupt the company’s optimistic growth scenario.
Find out about the key risks to this 10x Genomics narrative.
Build Your Own 10x Genomics Narrative
If you want to draw your own conclusions or dig further into the details, you can quickly create your own perspective right here in just a few minutes: Do it your way
A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Take control of your future and expand your investment horizons with fresh opportunities you won’t want to miss out on from Simply Wall Street’s top stock picks:
- Grow your income stream and maximize yield in today’s market by targeting companies featured in these 19 dividend stocks with yields > 3%.
- Tap into the next wave of innovation with AI-focused businesses. Find the standouts among these 25 AI penny stocks.
- Seize value where the market has overlooked potential by spotting undervalued companies showcased in these 892 undervalued stocks based on cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if 10x Genomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com